rgt001-075
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 29, 2022 (NCT05297045)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
GLP1R agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06867718 | Phase 2 | Jan 24, 2025 | Regor Pharmaceuticals Inc. |
| NCT06277934 | Phase 2 | Mar 8, 2024 | Regor Pharmaceuticals Inc. |
| NCT05297045 | Phase 2 | Mar 29, 2022 | Regor Pharmaceuticals Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Regor Pharmaceuticals Inc. | For profit | 3 | 3 | 1 | 2022 |
1 organizations
Page 1 / 1